Journal of Clinical Oncology

Vol. 44, Issue 19_suppl Issue 19_suppl 2026
340
Articles

Articles in this Issue

Machine learning-based ICU mortality prediction across hematologic malignancy subtypes: A comparative analysis using MIMIC-IV.

Shankar Biswas, Yashasvi Srivastava, Ayman Hamadttu Jul 01, 2026 pp. 262-262 10.1200/jco.2026.44.19_suppl.262

262 Background: Patients with hematologic malignancies face high ICU mortality, yet prediction models largely treat these...

Tumor NK ligand profiles as predictors of allogenic NK cell therapy responsiveness.

Nam H. B. Tran, Na Ly Tran, My T. T. Ngo et al. Jul 01, 2026 pp. 80-80 10.1200/jco.2026.44.19_suppl.80

80 Background: Although NK cells offer a versatile and safe therapeutic platform, the understanding of natural killer (NK)...

TGFβ-mediated overexpression of podoplanin serves as a potential diagnostic biomarker in acute promyelocytic leukemia.

Syed K. Hasan, Akash Maity Jul 01, 2026 pp. 264-264 10.1200/jco.2026.44.19_suppl.264

264 Background: Early diagnosis of acute promyelocytic leukemia (APL), driven by PMLRARA oncoprotein, is vital for surviva...

Admission-day predictors of terminal outcome in advanced cancer inpatients: Insights from a large Indian palliative care cohort.

Allwin Jesuraj, Seema Mishra, Rakesh Garg et al. Jul 01, 2026 pp. 339-339 10.1200/jco.2026.44.19_suppl.339

339 Background: Inpatient mortality in palliative care units ranges 10-30% globally, yet prognostic data from low- and mid...

Yttrium-90 resin microsphere transarterial radioembolization in unresectable hepatocellular carcinoma: Early results with scout dose–based lung shunt estimation and dosimetry.

Jasim Jaleel, Bharadwaj S. Mangu, Amar Mukund et al. Jul 01, 2026 pp. 155-155 10.1200/jco.2026.44.19_suppl.155

155 Background: Yttrium-90 TARE is an effective locoregional therapy for HCC. TARE traditionally requires 99mTc-MAA for lu...

Hepatic arterial infusion chemotherapy combined with camrelizumab and lenvatinib in the treatment of advanced hepatocellular carcinoma: A retrospective study.

Wei Dong, Zhuoni Huo, Haoran Zhao et al. Jul 01, 2026 pp. 98-98 10.1200/jco.2026.44.19_suppl.98

98 Background: PD-1 inhibitors combined with tyrosine kinase inhibitors have achieved encouraging efficacy in unresectable...

A novel oncolytic vaccinia virus armed with IL-21 and 4-1BBL for intravesical treatment of NMIBC: Preclinical efficacy and first-in-human safety evaluation.

Shun Zhang, Hailong Liu, Ding Xu et al. Jul 01, 2026 pp. 198-198 10.1200/jco.2026.44.19_suppl.198

198 Background: Oncolytic viruses are emerging cancer immunotherapies. For non–muscle-invasive bladder cancer (NMIBC), int...

Quantitative hazard visualization of radioisotope contamination risks in emergency settings following radium-223 therapy.

Soichi Makino, Kazunari Miyazawa, Koichi Morota et al. Jul 01, 2026 pp. 323-323 10.1200/jco.2026.44.19_suppl.323

323 Background: Radium-223 (Ra-223), an alpha-emitting radiopharmaceutical, is a cornerstone of modern theranostics. While...

Long-term neoadjuvant chemoradiotherapy combined with camrelizumab for locally advanced rectal cancer: A single-arm, prospective, phase II clinical study.

Chunbo Zhao, Qian Zhang, Li Li et al. Jul 01, 2026 pp. 93-93 10.1200/jco.2026.44.19_suppl.93

93 Background: Neoadjuvant chemoradiotherapy (nCRT) has brought out a higher rate of complete response and anal sphincter...

MicroRNA-197-3p to counteract chemoresistance in ovarian cancer via COL4A6 inhibition.

Yi-Hui Wu Jul 01, 2026 pp. 221-221 10.1200/jco.2026.44.19_suppl.221

221 Background: Collagen type IV alpha 6 (COL4A6) is overexpressed in ovarian cancer, where its elevated levels contribute...

Fruquintinib versus trifluridine-tipiracil plus bevacizumab versus regorafenib in refractory metastatic colorectal cancer: A propensity score–matched real-world analysis.

Shankar Biswas, Yashasvi Srivastava, Rahul Falodia et al. Jul 01, 2026 pp. 134-134 10.1200/jco.2026.44.19_suppl.134

134 Background: Fruquintinib, trifluridine-tipiracil plus bevacizumab (FTD/TPI+bev), and regorafenib are approved for refr...

Identification of independent prognostic factors in relapsed pediatric B-ALL patients receiving CD19 CAR-T without consolidative HSCT.

Ning Wang, Lipeng Liu, Junxia Wang et al. Jul 01, 2026 pp. 249-249 10.1200/jco.2026.44.19_suppl.249

249 Background: After CD19 chimeric antigen receptor (CAR) T-cell therapy (CAR-T), some B cell acute lymphoblastic leukemi...

Patient-reported outcomes for effective screening of chemotherapy-induced peripheral neuropathy.

Gowri Shivasabesan, Alice Treloar, Victoria Choi et al. Jul 01, 2026 pp. 350-350 10.1200/jco.2026.44.19_suppl.350

350 Background: Effective toxicity screening is necessary to improve cancer care. Chemotherapy-induced peripheral neuropat...

Shared tumor-reactive T cell clonotypes from tumor-infiltrating lymphocytes and tumor-associated lymph nodes defined by single-cell sequencing and tumor organoid models in non-small cell lung cancer.

Yin Li, Zhenjiang Liu, Ke Liu et al. Jul 01, 2026 pp. 275-275 10.1200/jco.2026.44.19_suppl.275

275 Background: Tumor-infiltrating lymphocytes (TILs) are a critical subset of immune cells in solid tumors, particularly...

Integrated fragmentomics and droplet digital PCR–based methylation analysis of cell-free DNA for enhanced detection of precancerous lesions and early colorectal cancer.

Thi Tuong Vi Van, Trang Thi Tran, Le Son Tran Jul 01, 2026 pp. 95-95 10.1200/jco.2026.44.19_suppl.95

95 Background: Early detection of colorectal cancer (CRC), particularly at the precancerous stage, is essential for reduci...

New and more drugs for early-stage cancers: Have they translated to more cures?

Laure-Anne Marie Nicole Teuwen, Brian Shkabari, Nicole Vorko et al. Jul 01, 2026 pp. 317-317 10.1200/jco.2026.44.19_suppl.317

317 Background: The U.S. Food and Drug Administration (FDA) oversees cancer drug approvals in the United States but has an...

BRIGHT-Fe: A phase III randomized trial of intravenous ferric derisomaltose vs low-dose oral iron polypeptide in iron-deficient early breast cancer receiving (neo)adjuvant chemotherapy.

Rakesh Pinninti, Raveena Gullapalli, Krishna Mohan Mallavarapu et al. Jul 01, 2026 10.1200/jco.2026.44.19_suppl.tps66

TPS66 Background: Iron deficiency anemia (IDA) is common in early breast cancer (EBC) patients receiving (neo)adjuvant che...

Site-specific conjugation of PEG12-PSMA ligand to dianthin by click chemistry to kill prostate cancer cells in the presence of the endosomal escape enhancer SO1861.

Kasun Madusanka Rajamanthrilage, Christopher Raab, Karina Monika Biskup et al. Jul 01, 2026 pp. 179-179 10.1200/jco.2026.44.19_suppl.179

179 Background: Prostate-specific membrane antigen (PSMA) is overexpressed in many prostate cancer cells and is a promisin...

Effect of long-limb Roux-en-Y reconstruction on early glycemic control compared with Billroth II after subtotal gastrectomy in patients with type 2 diabetes and gastric cancer: 6-Month interim analysis of the STARDOM trial.

Yeongkeun Kwon, Inyoung Lee, Mi Ran Jung et al. Jul 01, 2026 pp. 157-157 10.1200/jco.2026.44.19_suppl.157

157 Background: Gastrectomy can induce improvement in type 2 diabetes (T2DM), yet the metabolic impact may vary according...

Analytical cross-sectional study of correlation between plasma D-dimer levels and lymphovascular invasion in operable carcinoma breast.

Pradeep Balineni Jul 01, 2026 pp. 64-64 10.1200/jco.2026.44.19_suppl.64

64 Background: Malignancy is frequently associated with a hypercoagulable state due to tumour-induced activation of coagul...

Real-world comparative safety of first-line lorlatinib versus alectinib in metastatic ALK-rearranged non-small cell lung cancer: A propensity score-matched analysis.

Shankar Biswas, Yashasvi Srivastava, Rahul Falodia et al. Jul 01, 2026 pp. 283-283 10.1200/jco.2026.44.19_suppl.283

283 Background: Lorlatinib and alectinib are both NCCN-preferred first-line therapies for ALK-positive metastatic NSCLC, y...

Circulating tumor cell-based molecular classification to reveal heterogenous subclones in gestational trophoblastic neoplasia.

Xin Hong, Songfa Zhang Jul 01, 2026 pp. 222-222 10.1200/jco.2026.44.19_suppl.222

222 Background: Gestational trophoblastic neoplasia (GTN) is caused by cancerous transformation of placental trophoblastic...

Hepatic arterial infusion chemotherapy combined with transcatheter chemoembolization, camrelizumab, and apatinib for hepatocellular carcinoma with portal vein tumor thrombosis: A retrospective study.

Su-Yang Xue, Jiarui Li, Haifeng Zhang Jul 01, 2026 pp. 301-301 10.1200/jco.2026.44.19_suppl.301

301 Background: This study evaluated the combination of hepatic arterial infusion chemotherapy (HAIC), transcatheter chemo...

Unmet needs, quality of life, and lived experiences of patients with metastatic breast cancer in central Viet Nam: A convergent mixed-methods study.

Minh-Tri Phan, Ngoc-Thanh-Van Duong, Khoa Dang Cao et al. Jul 01, 2026 pp. 56-56 10.1200/jco.2026.44.19_suppl.56

56 Background: Metastatic breast cancer (mBC) imposes a significant burden in lower-middle-income countries, yet data on t...

Transformer-based multi-omics synthesis for early risk stratification and preventive surveillance in liver oncology.

Umesh Gangadhar, J. Singh, P. Kumar Jul 01, 2026 pp. 10-10 10.1200/jco.2026.44.19_suppl.10

10 Background: The efficacy of early intervention in liver oncology is frequently compromised by the profound molecular he...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page